| Drugs by Condition |  |
Respiratory Distress Syndrome Medications
Definition of Respiratory Distress Syndrome: A condition of the newborn marked by dyspnea with cyanosis, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.
Drugs (by generic name) associated with Respiratory Distress Syndrome
The following drugs and medications are in some way related to, or used in the treatment of Respiratory Distress Syndrome.
This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Drug Name  ( View by: Brand | Generic )
|
Reviews | Ratings |
|---|---|---|
beractant systemic (Pro, More...) class: lung surfactants | 0 Review(s) | Not rated - Be the first |
| calfactant systemic (Pro, More...)class: lung surfactants | 0 Review(s) | Not rated - Be the first |
| poractant systemic (More...)class: lung surfactants | 0 Review(s) | Not rated - Be the first |
Respiratory Distress Syndrome Medications in the Pipeline
Surfaxin (lucinactant)
- September 24, 2008
Discovery Labs Reports Technical Achievements Towards Gaining FDA Approval of Surfaxin - August 6, 2008
Discovery Labs Reports Progress in Responding to Surfaxin FDA Approvable Letter - June 19, 2008
Discovery Labs and FDA Meet to Clarify Limited Items in Surfaxin Approvable Letter - May 29, 2008
Discovery Labs and FDA to Meet On June 18, 2008 to Clarify Limited Items in Surfaxin Approvable Letter - May 5, 2008
Discovery Labs Provides Guidance On FDA Approvable Letter for Surfaxin for RDS - May 2, 2008
Discovery Labs Receives An Approvable Letter From FDA for Surfaxin for RDS - November 16, 2007
Discovery Labs' Response to Surfaxin Approvable Letter Deemed Complete by FDA - November 1, 2007
Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin for RDS in Premature Infants - October 1, 2007
Surfaxin Process Validation Batches Achieve Stability Milestone to Enable Filing of Response to FDA Approvable Letter - August 2, 2007
Discovery Labs Provides Update On Progress for Surfaxin for RDS - January 22, 2007
Discovery Labs and FDA Reach Clarity On Path Towards Surfaxin RDS Approval - September 28, 2006
Discovery Labs Updates Progress On Manufacturing Remediation and Surfaxin FDA Regulatory Matters - April 5, 2006
Discovery Labs Receives Second Approvable Letter From FDA for Surfaxin for RDS - October 21, 2005
FDA Accepts Discovery Labs' Complete Response to Approvable Letter for Surfaxin - August 19, 2005
Discovery Labs Provides Update on Status of Response to FDA Approvable Letter for Surfaxin - August 15, 2005
Discovery Labs Provides Status of Previously Submitted Response to FDA Approvable Letter for Surfaxin - July 29, 2005
Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin for RDS in Premature Infants - February 14, 2005
Discovery Labs Receives Approvable Letter from FDA for Surfaxin for Respiratory Distress Syndrome in Premature Infants - June 15, 2004
Discovery Laboratories Announces FDA Acceptance of Surfaxin New Drug Application - April 14, 2004
Discovery Laboratories Files New Drug Application with the FDA to Market Surfaxin for the Prevention of Respiratory Distress Syndrome in Premature Infants
